Melanoma/Skin Cancer News

More than 3 decades after receiving FDA approval, proton beam radiation therapy has failed to find a footing as a go-to treatment for many cancers in the United States.

The FDA granted priority review to tebentafusp for treatment of adults with HLA-A*02:01-positive metastatic uveal melanoma.

A lower dose of cyclophosphamide during preconditioning prior to tumor-infiltrating lymphocyte infusion appeared comparably effective but less toxic than a higher dose, according to results published in Journal for ImmunoTherapy of Cancer.

Researchers at Massachusetts General Hospital have discovered a skin pigment mechanism that could be developed into a topical drug aimed at reducing skin cancer risk, according to a study published in Cell.

A novel technique of low-dose rotational total skin electron beam therapy provided a fast and durable response in a small cohort of patients with skin lesions associated with cutaneous T-cell lymphoma.

The FDA granted priority review to pembrolizumab for adjuvant treatment of certain patients with high-risk melanoma.

The FDA granted fast track designation to nemvaleukin alfa for treatment of mucosal melanoma.

While melanoma incidence and prevalence in the U.S. increased between 1990 and 2019, mortality rates remained stable over that time, according to findings from a mathematical model.

A pediatric melanoma registry developed at St. Jude Children’s Research Hospital has helped researchers improve the classification of pediatric melanocytic tumors.

In 2010, results of the phase 2 BATTLE study demonstrated that choice of cancer therapy could be individualized based upon a patient’s tumor characteristics.